BNP And NTproBNP Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Type (BNP (Brain Natriuretic Peptide), NT-proBNP (N-terminal Pro-B-Type Natriuretic Peptide), By Location of Testing (Point Of Care Testing, Laboratory Testing), By Application (Myocardial Infarction, Congestive Heart Failure, Acute Coronary Syndrome (ACS), Others), By Region and Competition, 2020-2030F

Market Overview

The Global BNP And NTproBNP Market, valued at USD 1.92 Billion in 2024, is projected to experience a CAGR of 7.15% to reach USD 2.91 Billion by 2030. Brain Natriuretic Peptide (BNP) and N-terminal pro-B-type Natriuretic Peptide (NT-proBNP) are cardiac biomarkers secreted by cardiomyocytes in response to ventricular stretch or pressure overload, serving as critical diagnostic indicators for heart failure and other cardiovascular conditions. The market for these diagnostic assays is substantially driven by the increasing global incidence of cardiovascular diseases and the expanding geriatric population, which is particularly susceptible to cardiac ailments. Furthermore, the continuous advancement in diagnostic technologies and heightened awareness regarding early disease detection significantly support market growth. According to the American Heart Association, the worldwide population affected by heart failure surpassed 26.3 million in 2023.

However, a notable challenge impeding market expansion stems from the inherent limited specificity of BNP and NT-proBNP tests. Elevated levels of these biomarkers can result from various non-cardiac pathologies, including renal failure and pulmonary embolism, potentially leading to false-positive diagnoses and complicating clinical interpretation.

Key Market Drivers

The growth of the Global BNP and NTproBNP Market is significantly influenced by the escalating prevalence of cardiovascular diseases and the expanding geriatric population increasingly susceptible to heart conditions. The rising incidence of cardiovascular diseases necessitates widespread diagnostic and prognostic tools like BNP and NTproBNP assays for early detection and disease management. According to the World Health Organization, in 2022, an estimated 19.8 million people died from cardiovascular diseases, highlighting the profound global health burden these conditions impose. Concurrently, the increasing longevity of populations worldwide contributes to a higher prevalence of age-related cardiac ailments. This demographic shift directly fuels demand for cardiac biomarkers. According to Healthline, in October 2025, research indicates that as many as 78% of men and 76% of women aged 60 to 79 live with some form of heart disease, underscoring the substantial burden within the older demographic. Both factors collectively drive the need for accurate and timely cardiac diagnostics, expanding the market for BNP and NTproBNP testing.

This intensified demand fosters continuous innovation and investment within the heart failure diagnostics and therapeutics landscape. The development and funding of novel solutions directly support the ecosystem for established diagnostic biomarkers. For instance, according to EU-Startups, in October 2025, NanoPhoria Bioscience successfully raised €83.5 million in a Series A financing round to advance its lead therapy for heart failure with reduced ejection fraction, demonstrating significant investor confidence in addressing cardiac conditions globally. Such substantial financial backing for advanced heart failure treatments inherently reinforces the critical role of precise diagnostic tools, including BNP and NTproBNP, in patient stratification and monitoring within the broader cardiovascular care pathway.

Download Free Sample Report

Key Market Challenges

The inherent limited specificity of Brain Natriuretic Peptide and N-terminal pro-B-type Natriuretic Peptide tests significantly impedes market expansion. Elevated levels of these biomarkers can arise from various non-cardiac conditions, such as renal failure and pulmonary embolism, potentially leading to false-positive diagnoses and complicating clinical interpretation. This lack of singular diagnostic clarity diminishes confidence in the tests as standalone indicators for heart failure.

According to a study published by the European Society of Cardiology Heart Failure Association in October 2024, the current recommended NT-proBNP threshold of ≥125 pg/mL for heart failure referral demonstrates a specificity of only 50.0%. This implies that half of the patients tested who do not have heart failure could still present with elevated biomarker levels, necessitating further, often more expensive, confirmatory diagnostics. This complex diagnostic pathway reduces the efficiency and cost-effectiveness perceived by healthcare providers, directly hampering the broader adoption and utilization of BNP and NT-proBNP assays in routine clinical practice.

Key Market Trends

The expanding integration of point-of-care (PoC) testing represents a significant trend in the global BNP and NTproBNP market by decentralizing diagnostic capabilities and enabling rapid clinical decisions. PoC devices provide immediate results, crucial for managing acute cardiac events and enhancing patient throughput in emergency settings. This trend reflects a broader move towards more accessible and efficient diagnostic pathways. For instance, the American College of Cardiology in a journal scan from August 2024, highlighted a 2-hour strategy for point-of-care high-sensitivity cardiac troponin I testing in suspected acute myocardial infarction, underscoring the drive for expedited cardiac biomarker assessment. Further supporting this, Beckman Coulter received U. S. Food and Drug Administration clearance in May 2024 for its Access NT-proBNP assay, which provides heart failure assessment results in less than 11 minutes for emergency departments, demonstrating continuous innovation in rapid biomarker testing.

The increasing adoption of artificial intelligence and machine learning in diagnostics is also fundamentally transforming the market by improving accuracy and predictive power. These advanced analytical tools enhance the interpretation of complex biomarker data and integrate seamlessly with patient information to offer more precise diagnoses and personalized treatment strategies. The American Heart Association, in a scientific statement from February 2024, discussed how an AI/ML algorithm achieved 90.4% accuracy in identifying sex and an area under the curve of 0.97 in ECG analysis to predict biological age, signaling advanced capabilities in cardiovascular health assessment. Moreover, a study published in MDPI in August 2023 demonstrated the development of an AI-enabled electrocardiogram system with improved predictive abilities for mortality risk by detecting B-type Natriuretic Peptide and N-terminal pro-B-type Natriuretic Peptide levels, showcasing AI’s direct impact on BNP and NTproBNP utility.

Segmental Insights

In the Global BNP and NTproBNP Market, Point of Care Testing (POCT) stands out as the fastest-growing segment due to its significant clinical and operational advantages. This rapid expansion is primarily driven by the ability of POCT to provide immediate results, thereby facilitating faster clinical decision-making, particularly in emergency and acute care settings for conditions such as heart failure. Furthermore, POCT enhances patient convenience through on-site testing and improves resource utilization across various healthcare environments by reducing diagnostic turnaround times. The increasing adoption of these accessible and often cost-effective solutions is supported by established guidelines and certifications from regulatory bodies such as the College of American Pathologists and the Clinical and Laboratory Improvement Amendments (CLIA), underscoring their growing integration into standard clinical practice.

Regional Insights

North America leads the global BNP and NT-proBNP market primarily due to its advanced healthcare infrastructure and the high prevalence of cardiovascular diseases, which necessitates frequent cardiac assessments. The region benefits from robust regulatory frameworks, including approvals by the U. S. Food and Drug Administration for various BNP and NT-proBNP assays, alongside clear clinical guidelines from organizations like the American Heart Association. Furthermore, comprehensive reimbursement policies from bodies such as the Centers for Medicare & Medicaid Services ensure broad patient access to these critical diagnostic tests. The presence of key market players and research initiatives also drives continuous innovation and widespread adoption of these biomarkers across diverse healthcare settings.

Recent Developments

• In January 2025, Abbott received U.S. Food and Drug Administration (FDA) clearance for its Alere NT-proBNP assay, designed for use with the Alinity i system. This new test offered an additional tool for aiding in the diagnosis of heart failure by accurately measuring NT-proBNP levels, a key biomarker indicating cardiac stress. The assay was developed to ensure reliable results without significant biotin interference and provided streamlined workflows for laboratories, including 30-day on-instrument reagent stability. This expanded Abbott’s cardiac testing portfolio, enhancing its offerings in the Global BNP And NTproBNP Market.

• In June 2024, Gentian Diagnostics ASA unveiled a significant breakthrough in the development of its turbidimetric NT-proBNP assay. This new assay was designed to accurately measure NT-proBNP levels without interference from glycosylation, a common issue that can lead to underestimation of concentrations in clinical samples. This advancement facilitates more reliable NT-proBNP analysis on high-throughput clinical chemistry platforms, improving both cost-efficiency and workflow. The company aimed to make NT-proBNP testing more accessible and accurate for diagnosing and assessing the severity of heart failure, thereby enhancing patient management within the Global BNP And NTproBNP Market.

• In June 2024, Siemens Healthineers introduced its NT-proBNPII assay, integrating it into the Atellica Solution's cardiac testing menu. This new assay was designed to assist in the timely diagnosis of heart failure, providing initial results within approximately ten minutes. The addition of the NT-proBNPII assay expanded Siemens Healthineers' offerings, allowing for flexibility as both NT-proBNP and BNP tests could be conducted on their Atellica IM or Atellica CI analyzers. This product launch aimed to enhance diagnostic capabilities and support rapid clinical decision-making for patients with suspected or confirmed heart failure in various healthcare settings.

• In April 2024, Roche Diagnostics India launched a new point-of-care NT-proBNP test. This innovative test was specifically developed for screening diabetes patients at risk of cardiovascular diseases, particularly heart failure. Available on the cobas h 232 system, the biomarker extension aimed to provide faster and more efficient diagnosis and management for individuals with type 2 diabetes. The launch underscored the company's commitment to advancing healthcare through patient-centric solutions, facilitating early detection and intervention in primary care settings to improve outcomes for a high-risk patient population.

Key Market Players

• Specim, Spectral Imaging Ltd
• Gentian Diagnostics ASA
• Siemens AG
• PerkinElmer Inc
• Biomerieux SA
• Quidel Corporation
• Bio-Rad Laboratories, Inc.
• F. Hoffman-La Roche Ltd
• BHR Pharmaceuticals Ltd.
• Xiamen Biotime Biotechnology Co., Ltd.

Report Scope:

In this report, the Global BNP And NTproBNP Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• BNP And NTproBNP Market, By Type:

o   Brain Natriuretic Peptide

o   NT-proBNP (N-terminal Pro-B-Type Natriuretic Peptide)

• BNP And NTproBNP Market, By Location of Testing:

o   Point Of Care Testing

o   Laboratory Testing

• BNP And NTproBNP Market, By Application:

o   Myocardial Infarction

o   Congestive Heart Failure

o   Acute Coronary Syndrome (ACS)

o   Others

• BNP And NTproBNP Market, By Region:

o   North America

§  United States

§  Canada

§  Mexico

o   Europe

§  France

§  United Kingdom

§  Italy

§  Germany

§  Spain

o   Asia Pacific

§  China

§  India

§  Japan

§  Australia

§  South Korea

o   South America

§  Brazil

§  Argentina

§  Colombia

o   Middle East & Africa

§  South Africa

§  Saudi Arabia

§  UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Global BNP And NTproBNP Market.

Available Customizations:

Global BNP And NTproBNP Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Global BNP And NTproBNP Market is an upcoming report to be released soon. If you wish an early delivery of this report or want to confirm the date of release, please contact us at sales@techsciresearch.com